UHN Research

@UHN_Research

Research news from Canada's largest research hospital. Follow @BradWouters UHN's Executive Vice President Research for more research-related news and views.

Science

Early invikafusp alfa trial records no disease progression in 16 of 27 at optimal biological doses

NIH reports four of the 27 had targeted tumors shrink by more than 30% in the early trial.

9 Sources, 5h ago, first seen 5h ago

QR code linking to https://www.nature.com/articles/s41591-026-04711-0

Featured in

Early invikafusp alfa trial records no disease progression in 16 of 27 at optimal biological doses

Featured in

Early invikafusp alfa trial records no disease progression in 16 of 27 at optimal biological doses